CAR-T Cells for the Treatment of Lung Cancer
Luisa Chocarro 1, Hugo Arasanz 1 2, Leticia Fernández-Rubio 1, Ester Blanco 1 3, Miriam Echaide 1, Ana Bocanegra 1, Lucía Teijeira 2, Maider Garnica 1, Idoia Morilla 2, Maite Martínez-Aguillo 2, Sergio Piñeiro-Hermida 1, Pablo Ramos 1, Juan José Lasarte 4, Ruth Vera 2 5, Grazyna Kochan 1, David Escors 1
Adoptive cell therapy with genetically modified T lymphocytes that express chimeric antigen receptors (CAR-T) is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in hematological malignancies.
However, the efficacy of CAR-T cells in solid tumors is still very unsatisfactory, because of the strong immunosuppressive tumor microenvironment that hinders immune responses.
The development of next-generation personalized CAR-T cells against solid tumors is a clinical necessity. The identification of therapeutic targets for new CAR-T therapies to increase the efficacy, survival, persistence, and safety in solid tumors remains a critical frontier in cancer immunotherapy.
Here, we summarize basic, translational, and clinical results of CAR-T cell immunotherapies in lung cancer, from their molecular engineering and mechanistic studies to preclinical and clinical development.
Keywords: CAR-T; adoptive cell therapy; immunotherapy; lung cancer; solid tumors.
CITA DEL ARTÍCULO Life (Basel). 2022 Apr 8;12(4):561. doi: 10.3390/life12040561.